LIMMitless long-term results: Continuous risankizumab in moderate-to-severe plaque psoriasis

Long-term results of the phase III, open-label extension of the LIMMitless trial (NCT03047395) were published by Papp et al. in the American Journal of Clinical Dermatology. This trial evaluated the efficacy and safety of 150 mg risankizumab every 12 weeks over a duration of 324 weeks in 897 patients with moderate-to-severe plaque psoriasis (661 patients completed the study). 

Key data: At Week 324, risankizumab showed lower cumulative rates of serious adverse events (SAEs), at 6.7 vs 9.9 events/100 patient-years (E/100 PY), and treatment-emergent adverse events (TEAEs) leading to discontinuation, at 1.7 vs 2.7 E/100 PY, compared with Week 16. At Week 304, 86.0% of patients achieved Psoriasis Area and Severity Index (PASI) 90, 54.2% achieved PASI 100, 84.7% attained static Physician’s Global Assessment (sPGA) 0/1, and 76.3% achieved Dermatology Life Quality Index (DLQI) 0/1. 

Key learning: Risankizumab was well tolerated and showed high efficacy through 6 years of continuous treatment in patients with moderate-to-severe plaque psoriasis. The findings suggest risankizumab has the potential to improve outcomes in patients requiring long-term psoriasis management.